BioNTech (BNTX)
(Delayed Data from NSDQ)
$111.77 USD
-2.70 (-2.36%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $111.72 -0.05 (-0.04%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
BNTX 111.77 -2.70(-2.36%)
Will BNTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNTX
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs
Other News for BNTX
BioNTech and Moderna: A tale of two mRNA developers
BioNTech partial clinical hold an 'incremental negative,' says Morgan Stanley
BioNTech: FDA puts partial clinical hold on Phase 3 PRESERVE-003 trial
BioNTech, OncoC4 Phase 3 study put on partial hold by FDA
BioNTech’s Cancer Trial Faces FDA Hold Challenges